Does Blue Cross Blue Shield of Massachusetts Cover Lantus?

How BCBSMA Formulary Placement Works for Lantus

Blue Cross Blue Shield of Massachusetts organizes prescription drugs into tiers that determine patient cost-sharing. Lantus (insulin glargine, manufactured by Sanofi) appears on the BCBSMA formulary under its brand name, and the specific tier assignment depends on whether you carry a commercial HMO, PPO, or Medicare Advantage plan.

For most plan years since 2023, BCBSMA has listed Lantus as a Tier 2 or Tier 3 medication. Tier 2 carries a typical copay of $30 to $50 per fill on commercial plans, while Tier 3 ranges from $50 to $75 before any state copay cap applies. The distinction between these tiers frequently shifts during annual formulary updates, so checking the current formulary PDF on the BCBSMA member portal before filling a prescription remains the most reliable step.

Insulin glargine biosimilars like Semglee (Mylan/Viatris) and Rezvoglar (Eli Lilly) have moved onto Tier 2 in several BCBSMA plan designs, occasionally pushing brand-name Lantus to Tier 3. The American Diabetes Association's Standards of Care 2024 note that biosimilar insulins are clinically interchangeable with their reference products, meaning a tier shift to a biosimilar should not affect glycemic control [1].

Massachusetts Insulin Copay Cap Law

Massachusetts enacted Chapter 77 of the Acts of 2022, which caps the cost of a 30-day insulin supply at $25 for patients enrolled in state-regulated fully insured health plans. This law applies to most individual and small-group plans issued by BCBSMA within the Commonwealth.

The cap covers all insulin formulations, including Lantus SoloSTAR pens and Lantus 10 mL vials. Patients do not need to meet their deductible before the cap applies. According to the Massachusetts Health Policy Commission, roughly 200,000 Massachusetts residents with diabetes benefit from this cap [2].

Self-funded employer plans (ERISA plans) are exempt from state mandates. If your employer self-insures through BCBSMA as a third-party administrator rather than purchasing a fully insured product, the $25 cap may not apply. Your plan documents or HR department can confirm whether your coverage is fully insured or self-funded.

The Inflation Reduction Act separately caps insulin copays at $35 per month for Medicare Part D and Medicare Advantage prescription drug plans, including those administered by BCBSMA [3]. This federal cap took effect January 1, 2023, and applies regardless of whether Lantus sits on a preferred or non-preferred tier.

Prior Authorization and Step-Therapy Requirements

Most BCBSMA commercial plans do not require prior authorization for Lantus. The drug is dispensed at the pharmacy with a valid prescription from any licensed prescriber.

Some Medicare Advantage and certain high-deductible commercial plans do impose step therapy. In these designs, the plan may require documentation that the patient tried and failed (or has a contraindication to) NPH insulin or a biosimilar glargine before approving brand Lantus at the preferred copay tier. Step-therapy overrides typically require a letter from the prescribing clinician citing clinical rationale, such as hypoglycemia on NPH or a documented allergy to a biosimilar excipient.

A 2021 retrospective cohort study published in Diabetes Care (N=1,542 patients switched from brand glargine to biosimilar glargine) found no significant difference in HbA1c at 6 months (mean difference 0.02%, 95% CI -0.05 to 0.09) [4]. BCBSMA cites this type of evidence when implementing step-therapy protocols that favor biosimilars over brand Lantus.

If your plan denies Lantus coverage or places it on a non-preferred tier, your physician can file a formulary exception request. BCBSMA must respond within 72 hours for standard requests and 24 hours for expedited (urgent) requests under Massachusetts Division of Insurance regulations.

Comparing Lantus to Covered Biosimilar Alternatives

Three insulin glargine biosimilars have received FDA approval and appear on various BCBSMA formularies:

Semglee (insulin glargine-yfgn): Approved in 2020 as the first interchangeable biosimilar insulin in the U.S. The FDA approval letter confirmed interchangeability, meaning pharmacists in Massachusetts can substitute it for Lantus without prescriber intervention [5]. BCBSMA frequently places Semglee on Tier 2.

Rezvoglar (insulin glargine-aglr): Eli Lilly's biosimilar, approved in 2021. It appears on some BCBSMA commercial formularies, often at the same tier as Semglee.

Basaglar (insulin glargine): Marketed by Eli Lilly since 2016, Basaglar was approved through the 505(b)(2) pathway rather than the biosimilar pathway, so technically it is a follow-on biologic. BCBSMA has historically covered Basaglar on Tier 2 or Tier 3, and it remains an option for patients whose plans prefer it over brand Lantus.

The ORIGIN trial (N=12,537) established long-acting insulin glargine's cardiovascular safety profile over a median 6.2 years of follow-up, with no increase in major adverse cardiovascular events versus standard care [6]. This safety data applies equally to biosimilar glargine products that reference the same molecule.

How to Check Your Specific BCBSMA Plan

Formulary placement changes annually, and sometimes mid-year for Medicare Advantage plans. Here is the fastest verification path:

Log into the BCBSMA member portal at bluecrossma.org. Manage to "Find a Drug" or "Formulary Search." Enter "Lantus" or "insulin glargine." The tool will display tier, quantity limits, prior authorization flags, and any step-therapy notes specific to your plan ID.

Alternatively, call the number on the back of your BCBSMA card. Ask the representative three questions: (1) What tier is Lantus on my specific plan? (2) Is prior authorization required? (3) Does my plan fall under the Massachusetts $25 insulin copay cap?

Your prescriber's office can also run a real-time benefit check through their electronic health record system. This returns patient-specific copay estimates at the point of prescribing, which can guide the conversation about whether brand Lantus or a biosimilar makes more financial sense.

Out-of-Pocket Cost Scenarios

The actual amount you pay for Lantus under BCBSMA depends on several intersecting factors: your plan tier, whether you have met your deductible, and which state or federal copay caps apply.

Scenario 1: Fully insured commercial plan, $25 cap applies. You pay $25 for a 30-day supply regardless of tier placement. No deductible phase matters.

Scenario 2: Self-funded employer plan, Lantus on Tier 2. You pay your plan's Tier 2 copay (commonly $30 to $50) after meeting any applicable deductible. High-deductible health plans (HDHPs) may require full price until the deductible is satisfied, though the Sanofi Insulins ValYou Savings Program can reduce this to $0 for commercially insured patients [7].

Scenario 3: Medicare Advantage with Part D. The Inflation Reduction Act caps your cost at $35 per month per insulin. This applies in the deductible phase, initial coverage phase, and coverage gap.

Scenario 4: Uninsured or coverage gap. Sanofi's Lantus patient assistance program provides free insulin to qualifying patients with household incomes below 400% of the federal poverty level. The ValYou cash-pay program caps Lantus at $35 per pen box or vial for those not using insurance.

A 2023 analysis in JAMA Internal Medicine found that insulin out-of-pocket costs dropped 40% among Medicare beneficiaries in the first year after the IRA copay cap took effect, with the largest reductions among patients using long-acting analogs like glargine [8].

Clinical Context: Why Lantus Remains Widely Prescribed

Lantus was the first once-daily basal insulin analog approved by the FDA (2000), and it remains one of the most-prescribed insulins in the United States despite biosimilar competition. Its 24-hour duration of action and relatively flat pharmacokinetic profile made it a standard reference for basal insulin therapy in both type 1 and type 2 diabetes.

The EDITION trial program (EDITION 1, 2, 3, and JP) demonstrated that insulin glargine 300 units/mL (Toujeo) offered modestly lower nocturnal hypoglycemia rates compared to Lantus 100 units/mL in type 2 diabetes, though HbA1c reductions were comparable [9]. BCBSMA covers Toujeo as well, but it typically sits on a higher tier than Lantus or its biosimilars.

For patients with type 2 diabetes on basal insulin, the American Diabetes Association Standards of Care recommend initiating basal insulin at 10 units/day (or 0.1 to 0.2 units/kg/day) and titrating by 2 units every 3 days to reach a fasting glucose target of 80 to 130 mg/dL [1]. This applies regardless of whether the patient fills brand Lantus or a biosimilar.

Filing an Appeal if Coverage Is Denied

BCBSMA may deny Lantus in rare situations: the plan exclusively covers a biosimilar, the prescription exceeds quantity limits, or prior authorization was not obtained when required. Massachusetts law provides a structured appeals process.

Internal appeal: Submit within 60 days of denial. Include a letter of medical necessity from your prescriber explaining why brand Lantus is required (e.g., adverse reaction to biosimilar excipients, documented instability on alternative formulations). BCBSMA must decide within 30 days for standard appeals.

External review: If the internal appeal is denied, you may request an independent external review through the Massachusetts Office of Patient Protection. The external reviewer's decision is binding on the plan. According to the Massachusetts Attorney General's Health Care Division, external review overturn rates for prescription drug denials have averaged 40 to 50% in recent years [10].

Expedited appeal: If your physician certifies that delay would seriously jeopardize your health (e.g., you are currently using Lantus and a gap in supply would cause dangerous hyperglycemia), BCBSMA must resolve the appeal within 72 hours.

Specialty Pharmacy vs. Retail Pharmacy Dispensing

Lantus is not classified as a specialty medication by BCBSMA. It is dispensed at retail pharmacies (CVS, Walgreens, independent pharmacies) and through mail-order pharmacy programs. Mail-order typically offers a 90-day supply at a lower per-unit cost.

BCBSMA's mail-order pharmacy partner processes 90-day insulin fills, which can reduce your number of copays from 12 to 4 per year. Under the Massachusetts $25 cap, a 90-day supply would cost $75 (3 x $25) rather than requiring a separate pharmacy visit each month.

Some BCBSMA plans offer preferred pharmacy networks where copays are reduced by $5 to $10 compared to non-preferred retail pharmacies. CVS Caremark serves as the pharmacy benefit manager for many BCBSMA plans, so CVS locations frequently appear in the preferred network.

Transitioning Between Lantus and Biosimilars Under BCBSMA

If BCBSMA moves Lantus to a higher tier mid-year or during annual renewal, your prescriber may recommend switching to a covered biosimilar. The transition is straightforward because biosimilar glargine uses the same 100 units/mL concentration and identical dosing.

The Endocrine Society's 2023 position statement on biosimilar insulins confirms that patients can switch from reference insulin glargine to an interchangeable biosimilar at the same dose without additional monitoring beyond standard diabetes care [11]. No dose adjustment, titration period, or additional lab work is required.

Patients switching from Lantus SoloSTAR pens to Semglee pens should note that the pen devices differ mechanically. A brief demonstration from the pharmacist on proper injection technique with the new device is recommended by the CDC's Division of Diabetes Translation [12].